

INDEX

ABSORPTION

- buccal, 29
- chewing tobacco, 281
- cigarette smoke, 29, 281
- lung, 29
- nicotine polacrilex gum, 281
- other tobacco exposure, 29
- smoking behavior, 153

ABSTINENCE

- (See also CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYMPTOMS; WITHDRAWAL SYNDROME)
- aggression, 203
- spontaneous withdrawal assessment, 293
- weight gain, relapse predictor, 440
- withdrawal syndrome, reinforcement, 197

ACETYLCHOLINE

- desynchronization of electroencephalograms, 110
- high-affinity binding sites, 90, 92
- nicotinic cholinergic agonists, 81
- receptor measurement, 53
- release in cerebral cortex, 96
- turnover in hippocampus and frontal cortex, 98

ADDICTION

- definitions, 7, 149, 247-248, 249-250, 296
- effects of selected drugs, 299-303
- identification of hazardous drugs, 304
- nicotine and tobacco, 6, 8
- perceived functions of smoking, 397
- relationship to physical dependence, 296

ADOLESCENTS

- epidemiological studies, 261-262
- initiation of use, 259-265
- multidrug use, 259-265

ADOLESCENTS—Contd.

- negative- and positive-affect regulation, smoking, 399
- perceptions of stress, 121
- smoking prevalence, 573-577
- vulnerability factors, 266-267
- weight control and smoking, 438

ADVERTISING

- increased drug use, 305
- low-yield cigarettes, health risks, 566

AGE FACTORS

- body weight effects, 415, 416-418, 424, 431
- relapse, 316
- smoking cessation, 580-581
- smoking prevalence, 569, 579

ALCOHOL

- aversive stimuli, 280
- discriminative effects, 272
- multidrug use, 261-264
- place conditioning, 285
- prohibition and decreased use, 305
- reinforcement, 282

ALCOHOL CONSUMPTION

- abuse, smoking as risk factor, 401
- body weight, smokers vs. nonsmokers, 417-418, 431
- cigarette consumption effects, 167
- smoking prevalence among alcoholics, 402

ALKALOIDS, TOBACCO

- 2,3'-dipyridyl, structure, 27
- 6'-oxoanabasine, structure, 27
- anabaseine, structure, 27
- anabasine, structure, 27, 28
- anatabine, structure, 27, 28
- metanicotine, structure, 27
- myosmine, structure, 27, 28
- N'-formyl-nornicotine, content, 28
- N'-methylanabasine, structure, 27
- N'-methylanatabine, structure, 27

INDEX

- ALKALOIDS, TOBACCO—Contd.**
N'-nitrosornicotine, structure, 27
nicotine N'-oxide, structure, 27
nicotyrine, structure, 27
nornicotine, structure, 27, 28
nornicotyrine, structure, 27
pharmacologic effects, 56
pseudooxynicotine, structure, 27
- AMPHETAMINES**
cigarette consumption effects, 167
discrimination, 172, 275-276
- ANABASINE**
content, 28
discrimination, nicotine-trained animals, 172
respiratory and cardiovascular effects, 57
structure, 27
- ANTAGONISTS**
mecamylamine, 484-485
naloxone-precipitated withdrawal syndrome, 297
nicotine effects in brain, reinforcement, 192
precipitated withdrawal syndrome, 293
pretreatment, smoke intake, 166
- ANXIETY**
consumption increases, 404
deprivation, 405
neuroticism and adult smoking habit, 402
pain thresholds, abstinence vs. high-nicotine cigarettes, 406-407
reduction, affect regulation, smoking, 396, 397
reduction, cognitive appraisal, 411-412
weight gain, smokers vs. nonsmokers and ex-smokers, 422
withdrawal symptom, 199, 201, 204
withdrawal symptom, with nicotine polacrilex gum, 208, 210
- ARECOLINE**
discriminative stimulus, 172, 175
hippocampal theta activity, 109
- ATROPINE**
discrimination, nicotine-trained animals, 174
effects on desynchronization, 109
effects on radioligand binding, 90
- ATROPINE—Contd.**
low dependence potential, 285
- AUDITION**
amplitude decreases, withdrawal symptom, 204
auditory evoked response during smoking abstinence, 202
information task, smoking effects, 385
psychological enhancement and sensory gratification, 413
vigilance tasks, smoking effects, 383
- AUTONOMIC NERVOUS SYSTEM**
myenteric plexus, 96
peripheral cholinergic neuron stimulation, 79
phasic increases, emotional stimulation, 411
- AVERSIVE THERAPY**
contingency contracting, 494-495
covert sensitization, 488
directed smoking, 488
less severe techniques, 492-493
rapid smoking, 501
relaxation training, 493-494
unpleasant conditions, 501
- BEHAVIOR, ANIMAL**
associated stimuli, 309
drug seeking, 309
food intake and body weight, nicotine administration, 434
negative-affect-reducing properties of nicotine, 407
physical activity, nicotine administration and cessation, 435
place preference or aversion, 194-195
reinforcing drug effects, 279
self-administration of drugs, 279
- BEHAVIOR, HUMAN**
classically conditioned, 307
cocaine deprivation, 310
compulsive drug use, 250
counseling, 502-503
drug seeking, 310
nicotine self-administration, negative reinforcement, 193-194
nicotine self-administration, response rates, 192
operant, 307

INDEX

BEHAVIOR, HUMAN—Contd.
repetitive and stereotypic drug use,
8
respondent, 307
treatment strategies, 487-503

BELGIUM

body weight, smokers vs. nonsmokers
and ex-smokers, 419, 420

BIOASSAYS

cotinine and nicotine, 42-43
enzyme-linked immunosorbent assay,
43
gas chromatography, 43
mass spectrometry, 43
radioimmunoassay, 43

BIOCHEMICAL MARKERS

blood cotinine, 38, 42
blood nicotine, 42
carboxyhemoglobin, 42, 514
cotinine, 515
metabolism of nicotine, 41
salivary cotinine levels, 42
thiocyanate, 514-515
urinary cotinine levels, 42

BLACK AMERICANS

(*See also* ETHNIC GROUPS)
cessation motivation and success,
510
cessation of smoking, 508-509
church and fraternal roles, 511-512
coronary risk trial, 511
health care access, 509
physician influence, 511
quit-smoking treatments, 511-512
smoking and quitting patterns, 510
social norms and advertising, 509-
510
sociodemographic factors, 509

BLOCKADE THERAPY

mecamylamine, 484-485
opioid dependence, 484
tobacco dependence, 484-485

BLOOD

carboxyhemoglobin, 39
cotinine, 38
nicotine, 30-33, 38-39
pH and nicotine measures, 41
wound healing, 600

BLOOD PRESSURE

changes during abstinence or relapse,
202, 205

BLOOD PRESSURE

—Contd.

hypertension relationship to smoking,
600-601
stress and nicotine, 409

BODY HEIGHT

smokers vs. nonsmokers and ex-smokers,
416, 418

BODY TEMPERATURE

changes, withdrawal symptom, 202
skin, changes during abstinence or
relapse, 202, 205

BODY WEIGHT

adipose tissue, relative nicotine level,
32
carbohydrate metabolism and smoking,
107
changes during abstinence or relapse,
205
control, smoking and nicotine effects,
381
gains after nicotine cessation, animals,
432
hypothalamic consummatory drive
model, nicotine, 412-413
nicotine administration, animals,
with food intake, 434
nicotine polacrilex gum, effects, 432
smokers vs. nonsmokers and ex-smokers,
414-441
smoking cessation effects, 199, 202,
439
weight loss and nicotine, animals,
432

BRAIN

alpha, beta, and theta power, with
smoking, 111-112
anteroventral thalamic nucleus, 86,
94
blood-brain barrier, nicotine isothionium
penetration, 57
caudate nucleus, 94
central grey matter, 86-87
cerebellum, 94
cerebral cortex, 94
chemical mediation of nicotine, 8
cortical arousal, withdrawal symptom,
202, 204
cortical electric potentials, withdrawal
symptom, 206
cortical evoked potentials, withdrawal
symptoms with nicotine
polacrilex gum, 208

INDEX

BRAIN—Contd.

- dentate gyrus, 94
- electrocortical effects of nicotine, 107–112
- expectancy and orienting waves, 115
- frontoparietal cortex, 86–87
- glucose utilization, nicotine stimulation, 81, 86–88
- hippocampus, 94, 99–100, 109
- homovanillic acid levels after nicotine exposure, 110
- hypothalamus, 94, 97
- interanteromedial thalamic nucleus, 86
- interpeduncular nucleus, 86, 94, 95
- interpeduncular nucleus and medial habenula, ³H-labeled nicotine, 81
- lateral geniculate body, 86
- lateral habenulae, 86
- lateralized affective processors model, stressful conditions, 412
- locus coeruleus, 95
- medial habenulae, 86, 94, 95
- metabolism, binding sites, 85–86
- nerve cells, nicotine concentrations, 85
- nicotine concentrations, animals, 82–85
- nicotine levels, discrimination stimulus, 174
- nicotine polacrilex gum, 111–112
- nicotine-induced desynchronization, 109
- physiological effects of nicotine injections, 96–97
- presubiculum, 94
- putamen, 94
- rapid nicotine uptake, 32–33
- rat cerebellum, nicotine effects, 92–93
- relative nicotine level, 32
- retrosplenial cortex, 86
- substantia nigra pars compacta, 94
- superior colliculus, 86, 94
- ventral tegmental area, 86–88, 94

BUNGAROTOXIN

- binding sites, 47
- binding studies, mammalian brain, 91–94
- nicotinic cholinergic receptors, 88–89

BUNGAROTOXIN—Contd.

- receptor measurement, 53

CAFFEINE

- cigarette consumption effects, 167
- nonreinforcer, 281

CANADA

- body weight, smokers vs. nonsmokers and ex-smokers, 417

CARBON MONOXIDE

- carboxyhemoglobin content, 59
- smoking behavior, 154
- toxicity, 59
- visual information processing task, smoking effects, 384

CARBOXYHEMOGLOBIN

- carbon monoxide exposure, 59
- concentration, 39

CARCINOGENESIS

- benzo(a)pyrene-tetradecanoyl phorbol acetate, 604
- bladder, 604
- respiratory tract, 604
- tobacco cigarettes vs. nicotine polacrilex gum, 215

CARDIOVASCULAR SYSTEM

(See also CORONARY HEART DISEASE)

- acute tolerance, 48, 49
- atherosclerosis, 596–598
- body weight, smokers vs. nonsmokers and ex-smokers, 417, 422, 427
- carbon monoxide effects, 596
- cardiomyopathy, 599–600
- contribution of nicotine, 56
- coronary artery disease, 598
- low-density lipoproteins, 596
- nicotine and carbon monoxide, 116–117
- nicotine effects, 596–601
- stress and smoking, 118
- Surgeon General's Report, 12
- thrombosis, 597–598
- very low-density lipoproteins, 596

CATECHOLAMINES

- amniotic fluid, 603
- nicotine effects on central neurons, 100
- release from extra-adrenal chromaffin tissues, 97–98

INDEX

CELLS

nerve, nicotine concentrations, 85

CENTRAL NERVOUS SYSTEM

nicotine concentrations, 83-84
nicotine isomethonium, 57
nicotinic cholinergic receptors, 89
pre- or postsynaptic release of acetylcholine, 95
psychoactive drugs, 267
tranquilization effects of nicotine, 409

CESSATION OF SMOKING

(*See also* ABSTINENCE; DEPRIVATION; WITHDRAWAL SYMPTOMS; WITHDRAWAL SYNDROME)

blacks vs. whites, 572
criteria, 516
heavy vs. light smokers, success rates, 577
males vs. females, 580, 581
measurements, 576, 580
men, neuroticism, 402
physical activity changes, 435
program development, nicotine addiction, 6
quit attempts, 150
quit difficulty and daily consumption, 206
quit ratios by age and sex, 1965 to 1985, 581
relapse and psychophysiological reactivity, 120
spontaneous remission, 255-259
stages, 518
Surgeon General's Report, 12
trials, 489-490
weight gain, 414, 416, 422, 423, 424, 425, 431, 439-440

CESSATION OF SMOKING, METHODS

(*See also* NICOTINE DELIVERY, ALTERNATE; NICOTINE POLARILEX GUM; NICOTINE REPLACEMENT; TREATMENT)
acupuncture, 504
contingency contracting, 494-495
hypnosis, 504
nicotine addiction, 8-9
nicotine fading, 497-499
nicotine vapor inhaler, 212
self-efficacy, 497

CESSATION OF SMOKING,

METHODS—Contd.

similarity to methods for other drugs, 467
stimulus control, 497

CHEMICAL DETECTION

biological samples, 256, 259
interpretation, 259
sensitivity, 259
specificity, 259

CHEMICAL STRUCTURE

nicotine, 27
nicotine metabolites, 35
tobacco alkaloids, minor, 27

CHEWING TOBACCO

nicotine absorption, 29, 31
nicotine levels, 38

CHILDREN

negative- and positive-affect regulation, smoking, 399
smoking and body weight beliefs, 438

CHOLINERGIC AGENTS

acetylcholine release, 81
interaction with biogenic amine pathways, 98
nicotine effects on central and peripheral nervous systems, 96-97

CIGAR SMOKING

body weight, smokers vs. nonsmokers, 417, 419
nicotine levels, 38
prevalence, men, 1964 to 1986, 580, 582
Surgeon General's Report, 12

CIGARETTES, HIGH-NICOTINE

affect modulation, 405
blood nicotine levels, 39
brand loyalty, 567
carboxyhemoglobin levels, 39
effects on recall, 389
emphysema, 604
knee-jerk reflex, 45
visual information processing task, smoking effects, 384
yields of nicotine, 26

CIGARETTES, HIGH-TAR

brand loyalty, 567
visual information processing task, smoking effects, 384

INDEX

- CIGARETTES, HIGH-YIELD**
carbon monoxide, 59
heart rate, partial tolerance, 55-56
smoking behavior, 163
- CIGARETTES, LOW-NICOTINE**
affect modulation, 405
effects on recall, 389
emphysema, 604
knee-jerk reflex, 45
Surgeon General's Report, 12
visual information processing task,
smoking effects, 384
- CIGARETTES, LOW-TAR**
Surgeon General's Report, 12
visual information processing task,
smoking effects, 384
- CIGARETTES, LOW-YIELD**
carbon monoxide, 59
consumption, health risks, 566
heart rate, partial tolerance, 55-56
vented, smoke concentration, 159-
161
- COCAINE**
cost, 283-284
crack, 281
increase in use, 305-306
multidrug use, 261-264
place conditioning, 285
starter drug, 278
- COFFEE CONSUMPTION**
smokers vs. nonsmokers, 437
- COGNITION**
concentration difficulty, withdrawal
symptom, 199, 201, 204, 205,
208, 210
euphoria and dysphoria, 117
oral contraceptive use, response to
stress, 118-119
stressor response among women,
118
task performance, 394
- CONDITIONING**
behavioral tolerance, 289
cues to smoke, 465
drug use as learned behavior, 307-
309
drug-opposite response, 289
nicotine addiction, 465
pharmacologic and psychological
factors, 465
physiological reactions, 466
- CONDITIONING—Contd.**
place preference and aversion, 194,
284
placebo effects, 309
taste aversion, 194
- CONSUMPTION**
adolescents, 260
adolescents, stress factor, 400
adults, effects of stress, 401
body weight effects, 415, 416, 417,
419, 420, 423, 426, 431
children, smoking and body weight
beliefs, 438
frequency and multiple drugs, 263-
264
heavy smokers, stress, 403
heavy vs. light smokers, smoking
cessation success, 577
high-yield cigarettes, 163
multiple drugs, 260
occasional tobacco use, 253-254
prediction, 262-263
progression of drug use, 261-263
race, age, and gender factors, 579
severity of withdrawal symptoms,
206
United States, 1973 to 1987, 567
United States, estimation through
taxes, 565
United States, per capita decline,
565-566
- CONTROLLED SMOKING**
compensatory behavior, 499-500
outcomes, 499-500
parameters, 499
prospects for abstinence, 500
- COPING STRATEGIES**
cognitive versus behavioral tech-
niques, 530-531
retrospective bias, 531
self-punitive cognitions, 531
short- and long-term effects, 496
skill-based treatment, 532
skills training, 496
stimulus control, 530-531
stress and smoking habit, 402
willpower, 531
- CORONARY HEART DISEASE**
(*See also* **CARDIOVASCULAR SYS-
TEM**)
ischemia, mortality
myocardial infarct, 598-599

INDEX

CORONARY HEART DISEASE—

Contd.

myocardial infarct, weight gain after smoking cessation or continuation, 426

pharmacodynamic aspects, nicotine, 56

risk, 598

stress and smoking, 118

Surgeon General's Report, 11

CORTICOSTEROIDS

corticosterone and tolerance, 52

plasma corticosterone levels, 100-101, 103

plasma levels and cigarette smoking, 104-106

COST

alternate nicotine delivery systems, 214

individual and social, 252

positive and negative incentives, 284

required work, 283-284

time, 283

COTININE

bioassay comparison, 38-40

biochemical detection, 515

blood levels with nicotine polacrilex gum, withdrawal symptoms, 209

content, 28

daily cigarette consumption, 160

discrimination, nicotine-trained animals, 172

levels and severity of withdrawal symptoms, 206-207

metabolites, 34

nicotine metabolite, 34-38

structure, 27

tobacco-use marker, 38, 40

CRAVING

abstinence, 205

definitions, 295

gender difference, 523

measurement problems, 211

mecamylamine effects, 485

nicotine polacrilex gum, 208-209, 210, 475

plasma nicotine levels, 211

precipitating factors, 211

recurrent and persistent, abstinence, 8

relapse, 205, 523

CRAVING—Contd.

sensory stimuli, 211

smokeless tobacco withdrawal symptom, 207

withdrawal symptom, 199, 201, 204

CYTISINE

discrimination, nicotine-trained animals, 172-173

respiratory and cardiovascular effects, 57

DEMOGRAPHIC FACTORS

(See also SOCIOECONOMIC FACTORS)

cigarettes and smokeless tobacco, 306

marital status, 571

smoking prevalence, 569, 571

women and youth, 306

DENMARK

body weight, smokers vs. nonsmokers and ex-smokers, 418

DEPENDENCE

aversive limits, 268

behavioral effects, 286

cross-tolerance, 292

definitions, 7, 198, 247-248, 245-250

drug use, 12

interoceptive drug effects, 268

levels, 253

neuroadaptation, 286

physiological effects, 286

positive reinforcement, 268

potential testing, 269-270, 285-286

progression, 253

unconditioned stimuli, 268

DEPRESSION

Navy men, cigarette consumption, 404

nicotine polacrilex gum, 208-210

withdrawal symptom, 201

DEPRIVATION

(See also ABSTINENCE; CESSATION OF SMOKING; WITHDRAWAL SYMPTOMS; WITHDRAWAL SYNDROME)

attention span of smokers, 386

effects on memory, 388

negative affect, 405, 406

smoking rates and behavior, 164

stress, relapse, 402

INDEX

DIAZEPAM

- nicotine-induced antagonism, 175
- withdrawal syndrome, 297

DIET

- alkaline, smoking behavior, 163-164
- changes during abstinence or relapse, 205, 206, 433-434
- changes, smokeless tobacco withdrawal symptom, 207
- food intake and appetite, withdrawal symptom, 202
- food intake and smoking-related energy imbalance, 434
- hunger, hypothalamic consummatory drive model, nicotine, 412-413
- hunger, withdrawal symptom with nicotine polacrilex gum, 209, 210
- sweet food intake and weight gain after smoking cessation, 433-434

DISCRIMINATION

- behavior, 274
- drug similarity, 274
- generalization, 274
- intravenous nicotine administration, humans, 176-177
- metrazol, animals, 175
- nicotine, administration method, animals, 171-172
- nicotine, humans, 176-177
- nicotine, pentolinium pretreatment, 176-177
- nicotine vs. 3-methyl-pyridylpyrrolidine, 173
- specificity, 275-276
- testing, 274-277

DIZZINESS

- acute sensitivity, 45, 47
- tobacco poisoning, 595

DOPAMINE

- control over acetylcholine turnover, 98
- cue properties of nicotine, 97
- nicotine agonists, 54
- stimulation by nicotine, 54
- turnover and release, 100-101

DOSE CONTROL

- brand switching, 162
- consistent nicotine intake, 158
- function of time, 164
- nicotine reinforcement, animals, 189-190

DOSE CONTROL—Contd.

- ventilated cigarette holders, 159

DOSE-RESPONSE

- amphetamines, 282
- aversive limits, 282
- biphasic effects, 44
- compensatory nicotine intake, 283
- heart rate changes, 56
- psychoactivity, 272
- self-administration and reinforcement, 282
- self-reported effects, 274
- titration-studies, nicotine, 282-283
- tobacco smoke, 282
- withdrawal reactions, 293

DRUG ABUSE

- adolescents, smoking as risk factor, 400-401
- liability factors, 304

DYSPHORIA

- nicotine dose increases, 178

EDUCATION

- high school dropouts, smoking prevalence, 574
- smoking prevalence, 1985, 571

ELECTROENCEPHALOGRAPHY

- activating effects of nicotine, 81-82
- activity in rats, 52
- changes during abstinence or relapse, 205, 206
- distinct central nervous system effects, 108-109
- history of nicotine studies, 108-109
- nicotine-induced desynchronization, 112
- parallels with self-reports, 274
- power spectral analysis, 110
- withdrawal symptoms with nicotine polacrilex gum, 208

ELIMINATION

- acid loading, 40-41
- alkaline loading, 40-41
- kinetics, 38
- measurement of smoke intake, 152
- renal nicotine, 40-41
- tolerance measure, 289
- urinary tract, 33, 34, 36, 37

EMPHYSEMA

- Surgeon General's Report, 11
- weight gain, smokers vs. nonsmokers, 426

INDEX

ENDOCRINE

- adrenal cortex, 104-106
- follicle-stimulating hormone, 100-102
- growth hormone, 101
- luteinizing hormone, 100-102
- nicotine effects, 96
- prolactin, 100-102
- thyroid, 104
- thyroid-stimulating hormone, 100-102

ENVIRONMENTAL FACTORS

- conditioned responses, 306
- contingent reinforcement, 306
- drug costs, 306
- economic factors, 266
- individual reactions, 529
- negative affect, 530
- other smokers, 529-530
- parental drug use, 266
- peer smoking, 526
- place conditioning, 284-285
- relationship to direct drug effects, 308, 309
- smoking cues, 526, 529-530
- spousal smoking, 526-527
- stimulus control, 497
- stress, 530
- withdrawal effects, 204, 310-311

EPINEPHRINE

- levels during abstinence or relapse, 204, 205
- serum concentrations, 97

ETHNIC GROUPS

- (See also BLACK AMERICANS; HISPANIC AMERICANS)
- black Americans, 508-512
- black vs. white males, smoking prevalence, 569
- black vs. white pregnant smokers vs. nonsmokers, body weight, 418, 424
- blacks, smokers vs. nonsmokers and ex-smokers, body weight, 419
- blacks vs. whites, cigarette consumption, 577
- blacks vs. whites, smoking prevalence, 572, 579
- Hispanic Americans, 512-513
- Hispanic, smoking prevalence, 569-570
- Oriental alcoholism, 290

ETHNIC GROUPS—Contd.

- Oriental aversion to alcohol, 290

EX-SMOKERS

- body weight, vs. smokers and nonsmokers, 416-430
- spontaneous remission, 466
- withdrawal symptoms, 199-200

EYES

- nicotine concentrations, 83
- pupil enlargement after nicotine use, 274
- pupillary constriction from opioids, 291
- visual evoked response during smoking abstinence, 202

FINLAND

- body weight, smokers vs. nonsmokers and ex-smokers, 429

FRANCE

- body weight, smokers vs. nonsmokers and ex-smokers, 422

GANGLIA

- localization of nicotine, animals, 85
- peripheral cholinergic neuron stimulation, 79

GASTROINTESTINAL SYSTEM

- heartburn, 607
- peptic ulcer, 605-607
- relative nicotine level, 32
- small bowel, nicotine reabsorption, 33
- stomach, nicotine concentrations, 82-83

GENETIC PREDISPOSITION

- adolescent drug use, 266-267
- vulnerability factors, 266

HAIR

- nicotine recovery, 33

HEADACHE

- acute sensitivity, 45, 47
- tobacco poisoning, 595

HEART

- acute nicotine tolerance, 48, 49
- arrhythmia, 599
- nicotine concentrations, animals, 84
- relative nicotine level, 32

HEART RATE

- abstinence or relapse, 122-123, 202, 204, 205, 206

INDEX

- HEART RATE**—Contd.
acute tolerance, 48, 49
drug and environmental effects, 308
nicotine-induced tachycardia, 291
smokeless tobacco withdrawal symptom, 207
stress and nicotine, 409
stress and smoking, 118
tachycardia, 492–493
withdrawal symptom, 199, 201
withdrawal symptom with nicotine polacrilex gum, 210
- HEROIN**
cigarette consumption effects, 167
methadone effect, 288
- HEXAMETHONIUM**
acetylcholine release blocked, 81
attenuated amine release, 98
discrimination, nicotine-trained animals, 174
inhibiting effects on nicotine, 88, 92–93
smoke-induced edema, 179
- HISPANIC AMERICANS**
(See also **ETHNIC GROUPS**)
gender difference, 512
physician influence, 513
prevalence of smoking, 512
smoking cessation, 512–513
smoking correlates, 512–513
- HISTORICAL PERSPECTIVE**
addictive behavior, 269
discovery of nicotine, 10
medicinal vs. harmful effects, 9–10
nicotine addiction, 10–11
nicotine pharmacology, 10–11
tobacco use, 9
- HORMONES**
adrenocorticotropic, acetylcholine effects, 97
adrenocorticotropic, nicotine effects, 100–103, 105–106
androgen, testosterone levels, and smoking, 106
arginine vasopressin, nicotine-induced release, 102–103
estrogen production and metabolism, smoking effects, 106
pro-opiomelanocortin, acetylcholine effects, 97
- HORMONES**—Contd.
pro-opiomelanocortin, factors influencing release, 103–104
prolactin, luteinizing, and follicle stimulating, 52
- HYPOTHALAMUS**
consummatory drive model, nicotine, 412–413
neuroendocrine function, 52
- HYPOXEMIA**
fetal development, 603
subsequent behavioral abnormalities, 603
- IMPATIENCE**
nicotine polacrilex gum, 210
withdrawal symptom, 199, 201
- INHALATION PARAMETERS**
measurement techniques, 152
published values, 156–157
- INITIATION**
aversive reactions, 264–265
dependence, cigarettes vs. nicotine polacrilex gum, 215
drug classes, 259, 261–265
environmental motivations, 278
experimental use, 265
smokeless tobacco, 265, 584
social and pharmacologic factors, 264–265
stress and early smoking onset, 399
Surgeon General's Report, 12
weight control and smoking, 438
women, neuroticism, 402
- INTEROCEPTIVE EFFECTS**
definition, 170
dependence potential testing, 270–271
mood and feeling, 270
morning withdrawal cues, 307–308
perception, smoke and nicotine, 179
subjective pleasure, 308
taste, airway irritation, 179
- IRRITABILITY**
changes during abstinence or relapse, 205, 206
nicotine polacrilex gum, 208, 210
withdrawal symptom, 199, 201
- JAPAN**
body weight, smokers vs. nonsmokers and ex-smokers, 420

INDEX

KIDNEYS

- nicotine concentrations, 82-84
- nicotine elimination, 33, 37
- relative nicotine level, 32

LEARNING

- behavioral tolerance, 289
- letter-digit substitution task, smoking effects, 386-387
- nicotine and smoking effects, humans and animals, 386
- paired-associated, smoking effects, 387, 388
- serial, retention, smoking effects, 388
- state-dependent, definition, 389
- verbal rote, smoking effects, 387-388

LIVER

- drug detoxification and tolerance, 290
- nicotine concentrations, 83-84
- nicotine metabolism, 37
- relative nicotine level, 32

LOBELINE

- discrimination, nicotine-trained animals, 173
- respiratory and cardiovascular effects, 57

LOCOMOTOR ACTIVITY

- decreases with nicotine, 49, 51
- nicotine induced, 53

LUNG DISEASES

- bronchoconstriction, 604
- cancer, Surgeon General's Report, 11
- chronic bronchial wall inflammation, 603
- emphysema, 603
- nicotine toxicity, 603-604
- pulmonary epithelial permeability, 604
- Surgeon General's Report, 12

LUNGS

- afferent neuron stimulation, 116
- nicotine concentrations, animals, 84
- relative nicotine level, 32

LYSERGIC ACID DIETHYLAMIDE (LSD)

- nonreinforcer, 281, 282, 285

MAINTENANCE OF SMOKING

- Surgeon General's Report, 12

MAINTENANCE OF SMOKING—Contd.

- weight control, 438

MARIJUANA SMOKING

- cigarette consumption effects, 168
- multidrug use, 261-264
- smoking as risk factor, 401

MECAMYLAMINE

- brain and spinal cord effects, 89
- discrimination, nicotine-trained animals, 173-174
- dose-response, 93
- effects on desynchronization, 109
- local cerebral glucose utilization, 86-88
- nicotine conditioning taste aversion, 196
- nicotine-induced antagonism, 175
- nicotinic receptors blocked, 81
- place preference, nicotine effects, 195
- pretreatment, effect on conditioned reinforcer, 191
- pretreatment, harshness ratings of smoke, 179
- pretreatment, negative nicotine reinforcement, 193
- pretreatment, nicotine discrimination, 176-177
- pretreatment, nicotine polacrilex gum, discrimination, 178
- pretreatment, smoke intake, 166

MEMORY

- (See also RECALL)
- delayed, smoking effects, 388
- immediate, smoking effects, 388
- nicotine and smoking effects, humans and animals, 386
- recognition study, state-dependent, 390
- task performance, 394
- verbal, smoking and nicotine effects, 389
- words and order, smoking effects, 389

METABOLISM

- (See also PHYSICAL ACTIVITY)
- animal, body weight, smoke exposure or nicotine administration, 436
- body weight and smoking, 434, 435-437

INDEX

- METABOLISM**—Contd.
decreased, withdrawal symptom, 203
nicotine clearance, 40
nicotine metabolites, 34, 35, 36
rate, 37
smokers vs. nonsmokers, 53
smoking cessation effects, 433, 436
- METHADONE**
cigarette consumption effects, 167
effect on heroin use, 288
efficacy, 296
- MOOD**
changes during abstinence or relapse, 205-206
hedonic systems model, negative affect, 411
regulation, smoking and drug use, 401
regulation, subjective well-being, smoking effects, 394-399
- MORPHINE**
discrimination, 275-276
euphoria and self-administration, 277
physical dependence, withdrawal, 294
place conditioning, 285
- MOTIVATION**
behavioral tolerance, 289
gender differences, 506
self-perceived reasons for smoking, 398
treatment enhancement, 332-334
- MOTOR BEHAVIOR**
alcohol-induced muscle relaxation, 291
smoking and nicotine effects, 392-393
task performance, 394
- MUCOUS MEMBRANES**
cardiovascular effects of nicotine, 598
- MUSCLES**
alcohol-induced relaxation, 291
N-methylnicotinium ion, pressor and neuromuscular effects, 57
relative nicotine level, 32
tonic and phasic muscular activity, nicotine effects, 410
- MUTAGENESIS**
Salmonella typhimurium assays, 605
- NALOXONE**
cigarette consumption effects, 168
opioid withdrawal, 297
- NAUSEA**
acute sensitivity, 45, 47
tobacco poisoning, 595
- THE NETHERLANDS**
body weight, smokers vs. nonsmokers and ex-smokers, 430
- NEUROENDOCRINE FUNCTION**
nicotine effects, 95-96
- NEW YORK**
smokeless tobacco use, 1986, 581
- NEW ZEALAND**
body weight, smokers vs. nonsmokers and ex-smokers, 421
- NICOTINE**
content, different tobaccos, 28
intake, 40
place conditioning, 285
sensitivity, 46-47
structure, 27
- NICOTINE AEROSOLS**
respiratory sensations, plasma nicotine levels, 179-180
tobacco-like sensations, cessation method, 180
- NICOTINE CONTENT**
cigarettes vs. chewing tobacco, snuff, 28
high-yield cigarettes, 26
low-yield cigarettes, 26
- NICOTINE DELIVERY, ALTERNATE**
(See also CESSATION OF SMOKING, METHODS; NICOTINE POLACRILEX GUM; NICOTINE REPLACEMENT; TREATMENT)
chewable product, FDA ruling, 212-213
dependence potential, 214
nicotine polacrilex gum, dependence and withdrawal, 207-208
potential for abuse with concurrent tobacco use, 213-214
tobacco cigarettes vs. nicotine polacrilex gum, 215

INDEX

NICOTINE DELIVERY,

ALTERNATE—Contd.

- tolerance, physical dependence, withdrawal symptom alleviation, 212
- toothpaste-like formulation, FDA review, 212
- toxic effects, convenience, dependence potential, 213

NICOTINE FADING

- combination with self-monitoring, 498
- definition, 497
- low-tar and -nicotine brands, 497–498
- outcomes, 498–499

NICOTINE METABOLISM

- nicotine-1'-N-oxide, 36
- pathways, 34–37
- tachyphylaxis, 50

NICOTINE PHARMACOLOGY

- addictive properties, 6
- discrimination effects, 272
- pharmacokinetics, 25, 32
- stimulant and depressant effects, 79
- tobacco cigarettes vs. nicotine polacrilex gum, 215

NICOTINE POLACRILEX GUM

(See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE REPLACEMENT; TREATMENT)

- absorption, 29, 31
- affect modulation, 405
- blood levels of nicotine, 472
- body weight effects, 432
- combined with behavioral therapy, 476
- coronary heart disease, 599
- craving reduction, 475
- dose-patient relationship, 478–479
- duration of use, 478
- efficacy trials, 473–474, 475–478, 486
- fetal development, 602–603
- followup, 477
- mood regulation during smoking cessation, 406
- physical dependence, 210
- physician trials, 476–477
- poststimulus components, 115

NICOTINE POLACRILEX GUM—

Contd.

- pretreatment, smoking behavior, 165
- relapse, 477–478
- safety vs. cigarettes, 214–215
- stimulus effects, 178
- temporary treatment aid, 214
- toxicity, 213
- weight gain, 423
- withdrawal symptom alleviation, 207, 208, 472

NICOTINE REPLACEMENT

(See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE POLACRILEX GUM; TREATMENT)

- addiction treatment, 7
- aerosols, 480
- comparisons of preparations, 480–481
- dependence, 481
- forms and rationale, 471
- nasal solutions, 479
- polacrilex gum, 471–479
- side effects, 480
- transdermal patches, 479–480

NITROSAMINES

- American snuff, 605
- chemical structure, 606
- mainstream tobacco smoke, 605

NOREPINEPHRINE

- levels during abstinence or relapse, 205
- neuroendocrine activity, 101
- nicotine effects, 100–101
- release in hypothalamus, 97

NORNICOTINE

- content, 28
- discrimination, nicotine-trained animals, 172
- structure, 27

NORWAY

- body weight, smokers vs. nonsmokers and ex-smokers, 417, 418, 421, 426

OCCUPATIONS

- asbestos workers, 422
- civil servants, 422
- factory workers, 419
- farm workers, 594

INDEX

OCCUPATIONS—Contd.

- government workers, 418
- insurance company employees, 416
- manufacturing company employees, 419
- nurses, 439
- physicians, 438
- steel workers, 419
- telephone company employees, 420, 423

OPIOIDS

- addiction, 247
- addictive patterns, 282
- chipping, 253
- discriminative effects, 272
- fetal syndrome, 251–252
- physical dependence potential, 286–287
- protracted withdrawal, 253
- tolerance, 287
- withdrawal, 291–294

OXOTREMORINE

- discrimination, nicotine-trained animals, 172
- muscarinic cholinergic agonist, 52

PANCREAS

- body weight and smoking, 107

PASSIVE SMOKING

- Surgeon General's Report, 12

PEER GROUPS

- relapse, 321–322
- treatment, 334

PENTOBARBITAL

- depressant, cigarette consumption effects, 167
- discrimination, 275–276

PERFORMANCE

- impairment, withdrawal symptom, 204, 205, 206
- nicotine polacrilex gum, 203, 208
- problem solving, attention, and memory, 391

PERIPHERAL EFFECTS OF NICOTINE

- discriminative stimulus, 173
- overview, 79

PHARMACODYNAMICS

- cardiovascular changes, 55–56
- daily smoking patterns, 55
- definition, 25
- dose–response, 44

PHARMACODYNAMICS—Contd.

- tolerance, 44–46

PHARMACOLOGIC TREATMENT

- alprazolam, 482
- blockade therapy, 328
- clonidine, 328–329, 482–483
- deterrents, 329
- drug replacement therapy, 326–328
- mood changes, 483–484
- relief from withdrawal symptoms, 327
- symptomatic treatment, 328, 481–483

PHYSICAL ACTIVITY

(See also METABOLISM)

- body weight differences, smokers vs. nonsmokers, 434
- body weight, smoking cessation, 435
- decreased energy expenditure, withdrawal symptom, 203
- exercise tolerance, 600
- smokers vs. nonsmokers, 435

PIPE SMOKING

- body weight, smokers vs. nonsmokers, 417, 419
- coronary heart disease, 598
- nicotine levels, 38
- prevalence, men, 1964 to 1986, 580, 582
- Surgeon General's Report, 12

POLAND

- body weight, smokers vs. nonsmokers and ex-smokers, 420

POLYDRUG DEPENDENCE

- adolescents, 259–260
- frequency of use, 263–264
- initiation of cigarette and other drug use, 259–260
- prediction, 262–263
- preference tests, 272–273
- progression of use, 261–263
- tobacco-opioids-alcohol-stimulants, 254

POTENTIALS, SENSORY EVENT-RELATED

- auditory function and nicotine, 112–113
- contingent negative variation, 114–115

INDEX

- POTENTIALS, SENSORY EVENT-RELATED—Contd.**
visual function and nicotine, 113–114
- PREGNANCY**
amniotic fluid, nicotine recovery, 33
body weight, smokers vs. nonsmokers, 416, 418, 424, 426, 429
breast-milk fluid, nicotine levels, 33
low birth weight, 602
nicotine effects on animals, 602
perinatal mortality, 602
placenta, carbon monoxide and nicotine, 602
placenta, nicotine penetration, 33
prematurity, 602
spontaneous abortion, 602
- PRETREATMENT**
lidocaine, airway sensations, 169
nicotine, smoking behavior, 165–166
pentolinium, nicotine discrimination, 176–177
pimozide, taste aversion, 196
- PREVENTION OF SMOKING**
aversive smoking, 501–502
program development, nicotine addiction, 6
skills training, 501
- PSEUDOOXYNICOTINE**
structure, 27
- PSYCHIATRIC DISORDERS**
multiple diagnosis, 254
negative affect of smoking, 403
neuroticism, 401–402
tobacco-nicotine dependence and withdrawal, 12
- PSYCHOACTIVITY**
drug classification, 269–270
interoceptive effects, 270
mood and feeling, 270–271
tobacco cigarettes vs. nicotine polacrilex gum, 215
- PSYCHOMOTOR PERFORMANCE**
letter crossing tests, smoking effects, 384
smoking abstinence vs. nicotine polacrilex gum, 203
smoking and nicotine effects, 381
smoking effects, methodological limitations, 382
- PSYCHOMOTOR PERFORMANCE—Contd.**
Stroop test, nicotine effects, 385–386
sustained attention tasks, definition, 382
- PUFFING PARAMETERS**
definitions, 153
frequency, duration, volume, inter-puff interval, 153–154
interdependent relationships among measures, 153
measurement techniques, 151–152
published values, 156–157
visual information processing, smoking effects, 384
within-cigarette changes, nicotine dose, 155–158
- RAPID SMOKING**
aversive smoking cessation therapy, 196–197
cardiovascular and pulmonary risks, 493
comparison with other techniques, 492–493
conditioned aversive response, 492
rapid puffing, 501–503
single and multicomponent procedures, 491–492
stress, 494
tachycardia, 492–493
- REACTION TIME**
simple and complex, smoking effects, 392–393
smoking abstinence vs. nicotine polacrilex gum, 203
visual and auditory, smoking effects, 385
visual information processing, smoking effects, 384
visual, smoking effects, 383
- RECALL**
(*See also* MEMORY)
immediate, nicotine effects, 388
short- and long-term, nicotine tablets, 390
state-dependent, smoking vs. nonsmoking conditions, 390
verbal rote learning, smoking effects, 387–388
- RECEPTORS**
adaption to drug, 289
binding sites, minor alkaloids, 56

INDEX

RECEPTORS—Contd.

- constitutional tolerance, 290
- dihydro-beta-erythroidine, rat brain, 91
- disulfoton, ³H-nicotine binding, 54
- functional or pharmacodynamic tolerance, 289

RECEPTORS, CHOLINERGIC

- distribution of ³H-acetylcholine and ³H-nicotine, 80
- neuron stimulation, 79
- regulation of ³H-nicotine sites in mice, 80

RECEPTORS, NICOTINIC

- aversive effects of nicotine injections, 193
- binding sites, 53
- chronic tolerance, 53
- ganglionic and neuromuscular types, 88–89
- high-affinity sites, 90, 92–94
- locomotor activity, 53
- low-affinity sites, 90–91
- peripheral nervous system, 88–89
- primary and secondary binding sites, 86
- radioligand binding studies, 89–92
- tolerance, 54

REINFORCEMENT

- evaluation, 279–281
- negative, behavior modification, 193
- negative, nicotine injection, 193
- nicotine addiction, 6
- positive, continuous, intravenous nicotine, 182
- positive, intermittent, intravenous nicotine, 189, 190–191
- positive, nicotine, review, 183–188
- potential of various drugs, 305
- self-administration, 276–279
- stimulus effects, 268
- tobacco cigarettes vs. nicotine polacrilex gum, 215

REINFORCERS

- cocaine vs. nicotine, 189–190
- definition, 170
- positive, biobehavioral mechanism, dependence-producing drugs, 181–182
- psychoactive drugs, 8

RELAPSE

(See also SPONTANEOUS REMISSION)

- abstinence violation effect, 532
- age factors, 316
- alcohol and opioid dependencies, 316
- attribution theory, 525–526
- biochemical detection, 313
- correlates, 315, 317–319
- definition, 312, 518
- demographics, 520
- drug dependence severity, 315–316
- drug use, 8
- family support, 321, 324
- frequency of smoking, 521
- gender differences, 520
- high-risk factors, 519, 529–530
- long-term abstinence difficulties, 311
- measurement, 313
- negative emotions, 322–324
- peer drug use, 321–322
- prevention skills, 330–331
- psychiatric impairment, 316
- quitting history, 312, 522
- rates by drug class, 313–314
- self-efficacy, 524–525
- sensory cues, 121–123
- smoking history, 521
- social learning theory, 519
- treatment effectiveness, 315, 320–321
- treatment modalities, 312–313
- typologies, 521–522
- weight gain, risk factor, 440, 523–524
- withdrawal and dependence, 522–523
- withdrawal symptom alleviation, 205
- work and leisure activities, 322, 324

RESEARCH METHODS

- biochemical markers, 514–515
- carbon monoxide, 514
- carboxyhemoglobin, 514
- confounding design factors, 119–120
- cotinine assays, 515
- nicotine dosage control, 119
- self-reports, 515
- study design, 513–514
- suspect data, 514

INDEX

RESTLESSNESS

- changes during abstinence or relapse, 205
- nicotine polacrilex gum, 208, 210
- withdrawal symptom, 199, 201

ROLL-YOUR-OWN

- prevalence, men, 1964 to 1986, 580, 582

SALIVA

- nicotine secretion, 33
- tobacco poisoning, 595

SATIATION

- comparison with comprehensive procedure, 501-502
- single and multicomponent procedures, 488, 491

SELF-ADMINISTRATION

- abstinence symptoms, 310
- adjunctive, schedule-induced behavior, 278-279
- alcohol, 278, 281
- amphetamine, 278, 281
- animal research methods, 279-280
- behavioral process, 158
- cocaine, 278-281
- compulsive use, 149
- drive state, 277
- drug substitution, 278
- environmental pressure, 278
- free sampling, 277
- graduation, 277-278
- human and animal studies, 276-277
- human research methods, 280-281
- initiation, 277
- intravenous nicotine, response rates, humans, 192
- morphine, 278, 281
- nicotine, 278-281
- pentobarbital, 278, 281
- positive reinforcement, 276-277, 279
- reinforcing effects, 279-280
- reinitiation of drug use, 310
- voluntary conditions, 279

SENSATION

- environmental stimulus, conditioned reinforcers, 191
- place conditioning, 284
- psychological enhancement and sensory gratification, 413

SEROTONIN

- interneuronal communication system, 98
- pharmacological effects of nicotine, 99-100

SEX RATIO

- adolescents, weight control and smoking, 438
- body weight, smokers vs. nonsmokers, 415, 417, 421, 431
- cessation and relapse rates, 505-508
- education, 506-507
- heavy vs. light smokers, 577
- high school seniors, smoking prevalence, 574-576
- Hispanics, smoking prevalence, 569-570
- motivation to quit, 506
- neuroticism and adult smoking habit, 402
- smokeless tobacco use, 1970 to 1986, 580, 583
- smoking cessation rates, 580, 581
- smoking prevalence, 569, 572, 573, 579
- social support, 508
- social values and beliefs, 507
- stress and smoking, 118, 508
- weight gain after smoking cessation, 416, 433, 507-508

SLEEP

- disturbances, nicotine polacrilex gum, 208, 210
- disturbances, smokeless tobacco withdrawal symptom, 207
- disturbances, withdrawal symptom, 202, 204, 205, 206

SMELL

- aversion to alcohol, 280
- environmental stimulus, conditioned reinforcers, 191
- receptors, 58-59
- tobacco grade and type, 58-59
- tobacco smoke, place conditioning, 285

SMOKE CONSTITUENTS

- acetaldehyde effects, 60
- benzo(a)pyrene, 604
- brand switching, 162
- nonnicotine, tracheobronchial sensations, 168-169

INDEX

- SMOKE INHALATION, ANIMAL**
lungs, spleen, intestine, and brain,
nicotine concentrations, 84
- SMOKELESS TOBACCO**
(*See also* SNUFF)
addiction, with nicotine, 13
demographic changes, 306
nicotine dependence, 214
starter products, 265
withdrawal symptoms, 207
- SMOKELESS TOBACCO USE**
gum and mouth diseases and neo-
plasms, 213
prevalence, 1970 to 1986, 580, 583
- SMOKING ANTECEDENTS**
anxious, aggressive, and neurotic
personality traits, 402
personality measures, 402
stress, adolescents, 400
- SMOKING ARTICLES**
ventilated cigarette holders, 159
- SMOKING BEHAVIOR**
biochemical and behavioral mea-
sures, 154
carbon monoxide intake, 154
cigarette length, 161
consistent patterns, 155
measurement techniques, 150-152
perceived functions of smoking, 397
Surgeon General's Report, 12
switching cigarette brands, 161-162
taste and smell, 58-59
- SMOKING CONTROL PROGRAMS**
multicomponent, smoking cessation,
501-503
Surgeon General's Report, 12
- SMOKING HABIT**
negative- and positive-affect regula-
tion, 399
smoking-related disease diagnosis,
150
United States, adults, prevalence,
565-567
young adults, prevalence and con-
sumption, 578
- SMOKING SURVEYS**
adolescents, 573-577
Adult Use of Tobacco Survey, 572
Behavioral Risk Factor Surveil-
lance System, 573
Current Population Survey, 573
- SMOKING SURVEYS—Contd.**
Hispanic Health and Nutrition Ex-
amination Survey, 569-570
National Health Interview Surveys,
565-566, 568-569, 572
self-reported smoking status, un-
derreporting, 567-568
tobacco use trends, 9
- SNUFF**
(*See also* SMOKELESS TOBACCO)
angina pectoris, 600
dipping prevalence, 1970 to 1986,
580, 583
nicotine absorption, 29-31
nicotine levels, 38
paroxysmal hypertension, 600
- SOCIAL SUPPORT**
buddy system, 495
gender differences, 508
global support, 527
partner support, 527-528
smoking cessation, 526-527
spouse, 495
- SOCIOECONOMIC FACTORS**
(*See also* DEMOGRAPHIC FAC-
TORS)
body weight, smokers vs. nonsmok-
ers, 420, 428
ethnic, class, gender differences,
505
smoking prevalence, 1985, 571
treatment and prevalence, 467
- SPONTANEOUS REMISSION**
(*See also* RELAPSE)
comparison by drug class, 255-259
contributing factors, 255-259
studies, 257-258
- STATE-DEPENDENT LEARNING**
abstinence vs. smoking, 393-394
definition, nicotine, humans, 181,
389
nicotine effects, 387
- STATISTICAL ANALYSIS**
Addiction Research Center Invento-
ry, 271-272
discrimination procedures, 271
Morphine Benzadrine Group scale,
271-273
overlap of drug classes, 271
- STIMULANTS**
addiction, 247

INDEX

STIMULANTS—Contd.

- addictive patterns, 282
- discriminative effects, 272
- nicotine, 177

STRESS

- abstaining and coping, 528–529
- adult cigarette consumption, 401
- affect modulation, smoking and nicotine effects, 405–408
- affect regulation, smoking, 395–399
- consumption increases, 404
- elimination of nicotine, 41
- Hassles Scale, 528
- hedonic systems model, negative affect, 411
- initiation and consumption risk, 413–414
- lateralized affective processors model, 412
- low- vs. high-nicotine cigarettes, 405
- management skills, 332
- Navy men, smoking habit, 403–404
- nicotine polacrilex gum, 405
- nicotine withdrawal, conditioned responses, 408
- nurses, smoking habit, 403
- perceived stress, 528
- perceptual and pain-endurance thresholds, nicotine effects, 410
- psychophysiological reactivity, 117–122
- reduction, gender differences, 508, 528
- reduction, neurochemical role of nicotine, 408–409
- reduction, smokers vs. nonsmokers, 407
- relationship to relapse, 528–529
- risk factor for adolescent smoking, 399–401
- smoking and nicotine effects, 381
- smoking cessation relapse, 402, 528
- subjective well-being, smoking effects, 394–395

STUDENTS

- high school boys, body weight and smoking, 438
- high school seniors, smoking prevalence, 574–576
- junior and senior high school, stress and smoking initiation, 400

SWEDEN

- body weight, smokers vs. nonsmokers and ex-smokers, 428

SYMPATHETIC NERVOUS SYSTEM

- arousal regulation with nicotine, 409

TAR CONTENT

- sales-weighted average yield, 566
- smoking maintenance, 58
- tobacco taste characteristics, 58

TASTE

- environmental stimulus, conditioned reinforcers, 191
- first cigarette of day, 47
- menthol popularity among black Americans, 510
- receptors, 58
- tobacco cigarettes vs. nicotine polacrilex gum, 215
- tobacco grade and type, 58
- tobacco smoke, place conditioning, 285

TASTE AVERSION

- alcohol, 280
- apomorphine vs. nicotine, 196
- chlorisondomine, 196
- nicotine conditioning, animals, 195–196

TAXATION

- reflection of cigarette consumption, 565

TERATOGENICITY

- animals, 601
- humans, 601–602

THERAPY

- approved drug uses, 298
- deterrent, silver acetate, 485–486
- replacement, 326–328
- symptomatic, 328

TOBACCO CONSTITUENTS

- beta-carbolines, pharmacologic effects, 60

TOBACCO SUBSTITUTES

- smoke condensate, sensory effects, 169

TOLERANCE

- acquired reaction, 289
- acute, tachyphylaxis, 44, 47–50
- animal and human studies, 251

INDEX

TOLERANCE—Contd.

- behavioral, 44
- behavioral and physiological responses to nicotine, 197
- chronic, 44, 50–54
- constitutional reaction, 290
- cross-tolerance, 288, 292
- dependence potential testing, 286
- dose escalation, 50, 51
- intoxication, 251
- limits on escalation, 286–287
- measures, 288
- mechanisms, 288–290
- nicotine addiction, 6
- nicotine uptake, 8
- pharmacodynamic, functional, 44
- pharmacokinetic, dispositional, 44
- toxic effects, 45

TOXICITY

- acute, 593–596
- acute sensitivity, 45, 46
- children, 595
- chronic, 596
- nicotine polacrilex gum, 595–596
- physiological and psychological, 252

TREATMENT

- (See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE POLACRILEX GUM; NICOTINE REPLACEMENT)
- abstinence maintenance, 503
 - behavioral strategies, 329–334
 - blockade therapy, 328
 - clonidine, 328–329
 - family support, 333
 - goals, 325
 - leisure activity skills, 331–332
 - loss of control, 325
 - methodology, 513–516
 - motivation enhancement, 332–334
 - nicotine polacrilex gum, maintaining physical dependence, 210
 - overview, 465–470
 - peer support, 334
 - pharmacologic approaches, 326–329
 - professional contact, 333
 - relapse prevention skills, 330–331
 - relief from withdrawal symptoms, 327
 - replacement therapy, 326–328
 - stress management skills, 332
 - symptomatic therapy, 328

TREMOR

- hand, changes during abstinence or relapse, 205
- smoking effects, 392

TWINS

- body weight, smokers vs. nonsmokers, 417

TYROSINE HYDROXYLASE INHIBITOR

- histofluorescence studies, 100

UNITED KINGDOM

- Wales, body weight, smokers vs. nonsmokers and ex-smokers, 416

URINE

- acidification and cigarette consumption, 163
- cotinine, 36, 37
- nicotine isomethonium, 57
- nicotine-N-oxide, 36, 37
- pH and stress, 41
- unchanged nicotine content, 33

VISION

- conditioned reinforcer, nicotine delivery, 191
- environmental stimulus, 191
- information processing task, smoking effects, 384
- peripheral vision monitoring, smoking effects, 385
- place conditioning, tobacco smoke, 285
- psychological enhancement and sensory gratification, 413
- rapid visual information task, smoking effects, 385
- vigilance tasks, nicotine tablet effects, 383
- vigilance tasks, smoking effects, 383

WEST VIRGINIA

- smokeless tobacco use, 1986, 581

WITHDRAWAL SYMPTOMS

- (See also ABSTINENCE; CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYNDROME)
- aggression, 203
 - anxiety, 199, 201, 204, 208, 210
 - behavioral and physiological sequelae, 251
 - biting, animals, 204–205

INDEX

WITHDRAWAL SYMPTOMS—Contd.

body temperature changes, 202
concentration difficulty, 199, 201, 204, 205, 208, 210
conditioned drug seeking, 310
craving, 199, 201, 204, 208–209, 210
depression, 201, 208–210
electroencephalography changes, 208
environmental and pharmacologic factors, 198
environmental stimuli, 310
fatigue, 201, 202, 205
further drug intake, 8
hearing amplitude decreases, 204
hunger, food intake, 202, 207, 209, 210, 412–413, 434
hypothalamic consummatory drive model, nicotine, 412–413
identified, 198–199
increased heart rate, 210
irritability, impatience, 199, 201, 208, 210
measurements and techniques, 199–200
metabolism changes, 203, 433, 436
negative affect reduction, nicotine, 408
nervousness, 199, 201
nicotine blood levels with nicotine polacrilex gum, 209
nicotine polacrilex gum, 207, 208, 472
opioids, 291, 292
performance, 208
physical complaints, 199, 201, 208
plasma nicotine levels and symptom severity, 206–207
rebound phenomena, 204
respiration rate decrease, 202
restlessness, 199, 201, 208, 210
sleep disturbances, 202, 204, 205, 206, 207, 208
stress, 402, 408, 528, 529

WITHDRAWAL SYMPTOMS—Contd.

tobacco cigarettes vs. nicotine polacrilex gum, 215
weight gain, 414, 416, 422, 423, 424, 425, 431, 438, 439–440, 523

WITHDRAWAL SYNDROME

(*See also* ABSTINENCE; CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYMPTOMS)

American Psychiatric Association, recognition, 295
autonomic measures, 291
behavioral, 291
dependence potential testing, 286
distinctive signs, 296–297
evidence of addiction, 6, 294–295
precipitated responses, 293
protracted, 253
somatomotor measures, 291
spontaneous reactions, opioids and depressants, 292
variability, 294–295

WOMEN

black, smoking prevalence, 569
body weight, smokers vs. nonsmokers, 420
education, 506–507
electroencephalograms of neonates from smokers, 112
prolactin and breast feeding, smoking effects, 102
smoking prevalence, 569
social factors, 507–508
stress and smoking, 400, 508
Surgeon General's Report, 12
treatment programs, 467
weight control, 439, 507–508
weight gain, 523

WORKPLACE

Surgeon General's Report, 12

YUGOSLAVIA

body weight, smokers vs. nonsmokers and ex-smokers, 425